Trends in genitourinary cancer mortality in the United States: analysis of the CDC-WONDER database 1999–2020
Yahia Ghazwani, Mohammad Alghafees, Mahammed Khan Suheb, Areez Shafqat, Belal Nedal Sabbah, Tarek Ziad Arabi, Adhil Razak, Ahmad Nedal Sabbah, Marwan Alaswad, Wael Al-Kattan, Abderrahman Ouban, Saleha Abdul Rab, Kenan Abdulhamid Shawwaf, Mohammad Alkhamees, Ahmed Alasker, Abdullah Alkhayal, Bader Alsaikhan, Abdulmalik Addar, Lama Aldosari, Abdullah A. Al Qurashi, Ziyad F. Musalli
Abstract
Introduction: Sociodemographic disparities in genitourinary cancer-related mortality have been insufficiently studied, particularly across multiple cancer types. This study aimed to investigate gender, racial, and geographic disparities in mortality rates for the most common genitourinary cancers in the United States. Methods: < 0.05. Results: Overall, AAMRs for prostate, bladder, and kidney cancer declined significantly, while testicular cancer-related mortality remained stable. Bladder and kidney cancer AAMRs were 3-4 times higher in males than females. Prostate cancer mortality was highest in black individuals/African Americans and began increasing after 2015. Bladder cancer mortality decreased significantly in White individuals, Black individuals, African Americans, and Asians/Pacific Islanders but remained stable in American Indian/Alaska Natives. Kidney cancer-related mortality was highest in White individuals but declined significantly in other races. Testicular cancer mortality increased significantly in White individuals but remained stable in Black individuals and African Americans. Genitourinary cancer mortality decreased in metropolitan areas but either increased (bladder and testicular cancer) or remained stable (kidney cancer) in non-metropolitan areas. Prostate and kidney cancer mortality was highest in the Midwest, bladder cancer in the South, and testicular cancer in the West. Discussion: Significant sociodemographic disparities exist in the mortality trends of genitourinary cancers in the United States. These findings highlight the need for targeted interventions and further research to address these disparities and improve outcomes for all populations affected by genitourinary cancers.